Longitudinal changes in placental biomarkers in women with early versus late placental dysfunction
- 23 August 2019
- journal article
- research article
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 38 (4) , 268-277
Abstract
Objective: To evaluate longitudinal changes of angiogenic biomarkers in early- (EO-PD) versus late-onset (LO-PD) placental dysfunction. Methods: Serum PlGF and sFlt-1 measured at different intervals in EO-PD (n= 43), LO-PD (n= 31) and controls (n = 133). Results: sFlt-1/PlGF ratio was higher at 16 weeks (30.6 vs 17.5), 20 weeks (29.3 vs 8.9) and 30 weeks (16.6 vs 6.7) in EO-PD vs controls (all p< 0.05), but not in LO-PD. Longitudinal changes for all intervals had higher AUC than single measurements. Conclusion: Longitudinal biomarker change between 12 and 30 weeks could improve prediction of EO-PD compared to single measurements.Keywords
This publication has 49 references indexed in Scilit:
- Placental growth factor (PlGF): a key to optimizing fetal growthThe Journal of Maternal-Fetal & Neonatal Medicine, 2013
- Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic TherapiesGenes & Cancer, 2011
- Placental bed disorders in preterm labor, preterm PROM, spontaneous abortion and abruptio placentaeBest Practice & Research Clinical Obstetrics & Gynaecology, 2011
- The “Great Obstetrical Syndromes” are associated with disorders of deep placentationAmerican Journal of Obstetrics and Gynecology, 2011
- Antenatal magnesium sulphate may prevent cerebral palsy in preterm infants-but are we convinced? Evaluation of an apparently conclusive meta-analysis with trial sequential analysisBJOG: An International Journal of Obstetrics & Gynaecology, 2010
- Soluble fms-Like Tyrosine Kinase 1 (sFlt1), Endoglin and Placental Growth Factor (PlGF) in Preeclampsia among High Risk PregnanciesPLOS ONE, 2010
- Effect of Antihypertensive Therapy with Alpha Methyldopa on Levels of Angiogenic Factors in Pregnancies with Hypertensive DisordersPLOS ONE, 2008
- The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational ageThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonateThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- Sequential Changes in Antiangiogenic Factors in Early Pregnancy and Risk of Developing PreeclampsiaHypertension, 2007